Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC

Starting soon · Not applicable

Conditions studied: Initially Unresectable Hepatocellular Carcinoma

In brief

This study evaluates a novel "Dual-Conversion" strategy (mechanical volume conversion via LVD plus biological conversion via cTACE, Tislelizumab, and Lenvatinib) for patients with initially unresectable right-sided hepatocellular carcinoma (HCC). The primary goal is to assess the rate of successful conversion to R0 resection and the safety profile of this multi-modal approach.

Key facts

Study ID

NCT07480382

Run by

Hong Wu

People needed

30

Starts

2026-04-01

Expected to finish

2028-06-30

Last updated by the study team

2026-03-18

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-75 years.
• Confirmed HCC (histologically or by AASLD clinical criteria).
• Initially unresectable HCC limited to the right liver (due to insufficient FLR or tumor characteristics).
• Child-Pugh score ≤ 7 (Class A or early B).
• ECOG Performance Status of 0 or 1.
• Adequate organ function (marrow, hepatic, and renal).

You may not qualify if…

• Extrahepatic metastasis.
• Portal vein tumor thrombus involving the main trunk (Vp4).
• Previous systemic therapy for HCC.
• Active autoimmune disease or history of organ transplantation.
• Contraindications to LVD, TACE, or the study drugs

Where it is running

• West China Hospital, Sichuan University — Chengdu, Sichuan, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.